CHICAGO, August 14, 2015 /PRNewswire/ --
The latest market research report "Life Cycle Management Strategies - Optimizing revenues and defending generic competition" discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies.
Complete report on life cycle management market spread across 100 pages and talking about 19 companies is now available at http://www.reportsnreports.com/reports/413172-life-cycle-management-strategies-optimizing-revenues-and-defending-generic-competition.html .
This new 2015 life cycle management market strategies report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on. Starting with an introduction of LCM and product life cycle, this research covers information on objectives of LCM and factors impacting the choice of strategies, LCM strategies depending on the way of approach as well as impact of LCM strategies on sales and growth trend of selected products. Additionally, patent term extension and market exclusivity in the US and Europe, LCM strategies of pipeline drugs of key players and keys to successful implementation of LCM strategies are also provided.
Companies mentioned in the report are AbbVie, Actavis, AstraZeneca, Cipla, Gilead, GlaxoSmithKline, Gleevec, Janssen, MannKind, Merck, Novartis, Orexo, Otsuka, Pfizer, Roche, Salix Pharmaceuticals, Sanofi-Aventis, Solvay, Teva and Vifor Pharma. Order a copy of Life Cycle Management Strategies - Optimizing revenues and defending generic competition market research report at http://www.reportsnreports.com/Purchase.aspx?name=413172 .
This research helps identify the key LCM strategies used by most of the pharmaceutical companies and analyze the strategies to increase lifecycle and revenues of a drug. It also offers an understanding on the implementation of multiple strategies for a single product by including case studies as well as the operational pipeline strategies of key players. Major points covered in the table of contents for this report include:
Overview of Product Life Cycle
Product Life Cycle Curve
Objectives of Life Cycle Management (LCM)
Classification and Benefits of LCM Strategies
Strategic Planning for LCM
Factors Impacting Choice of LCM Strategies
Indication Expansion/Sequencing and Repositioning
Patient Subpopulations and Personalized Medicine
New Dosage Forms
New Route of Administration
New Dosage Strengths and Regimen
Fixed-Dose Combination and Co-packaging
Next Generation Products and Modified Chemistry
Multiple Developmental Strategy Approach
Pricing Strategy and Tactics
Pricing Strategy for Targeting Multiple Indications
Awareness, Brand Loyalty and Service Programs
Regulatory and Legal Strategies
Legal Defense and Pay for Delay
Patent Term Extension and Market Exclusivity
The Pharmaceutical Pipeline and LCM
Successful Implementation of LCM Strategies
For the pharmaceuticals market and its related segments, ReportsnReports.com has multiple newly published as well as relevant research titles:
Global Human Insulin Market 2015-2019: Analysts forecast global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019. The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market. Lilly, Novo Nordisk, Sanofi, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals,Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt and XOMA are some of the companies mentioned in this research available at http://www.reportsnreports.com/reports/413136-global-human-insulin-market-2015-2019.html .
Global Vaccine Market to 2019 - Market Size, Development, Top 10 Countries, and Forecasts: This industry research package offers the most up-to-date market data on the actual market situation, and future outlook for vaccines in the world and in the top 10 global countries covering China, France, India, Indonesia, Italy, Japan, Mexico, South Korea, United Kingdom and United States. The report included historic market data from 2008 to 2014 and forecasts until 2019 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key industry data in readily accessible and clearly presented tables and graphs. Human vaccines and veterinary vaccines are the product segments covered in this research. Read more at http://www.reportsnreports.com/reports/408129-global-vaccine-market-to-2019-market-size-development-top-10-countries-and-forecasts.html .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
1 South Dearborn Street,
21st Floor, Chicago,
IIIinois 60603, USA.
+ 1 888 391 5441
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts